Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Sinusitis Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market – Optinose, GeneOne Life Science, Lyra, Sanofi, Regeneron, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer

Published

on

<!– Name:DistributionId Value:8831877 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:19cd81b4-73a6-41ad-b0c8-6e6bedb3ab35 –>

New York, USA, May 09, 2023 (GLOBE NEWSWIRE) — Sinusitis Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market – Optinose, GeneOne Life Science, Lyra, Sanofi, Regeneron, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer

The sinusitis market is anticipated to surge due to the factors such as the launch of novel drugs, increasing healthcare spending and improved diagnosis during the forecasted period (2023–2032) in the 7MM. 

DelveInsight’s Sinusitis Market Insights report includes a comprehensive understanding of current treatment practices, sinusitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Sinusitis Market Report

  • As per DelveInsight analysis, the sinusitis market is expected to grow positively owing to several underline factors during the study period (2019–2032).
  • DelveInsight’s analysis shows that sinusitis cases show an increasing trend in the forecasted period in the United States. 
  • Globally, leading sinusitis companies such as Optinose US Inc, GeneOne Life Science, Lyra Therapeutics, Sanofi, Regeneron Pharmaceuticals, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer, TRELLIS BIOSCIENCE, Sanotize Research and Development, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., BEAM Alliance, Insmed Incorporated, Lanier Biotherapeutics, GlycoMira, IVIEW Therapeutics Inc., Nota Laboratories LLC, Quorum Innovations, and others are developing novel sinusitis drugs that can be available in the sinusitis market in the coming years.
  • Some of the key therapies for sinusitis treatment include OPN-375, Quinine topical nasal spray, Mometasone eluting resorbable scaffold, Dupilumab, Omalizumab, Benralizumab, Telithromycin, Moxifloxacin, PF-06817024, and others.
  • Several sinusitis therapies are in various stages of development, and their anticipated launch will drive the sinusitis market forward. 

Discover which therapies are expected to grab the major sinusitis market share @ Sinusitis Market Report

Sinusitis Overview

Sinusitis is one of the most common primary care diagnoses. It causes significant morbidity, often necessitating time away from work, and is one of the most common reasons why a general practitioner will prescribe antibiotics. Sinusitis is defined as inflammation of the mucosal lining of the paranasal sinuses. However, rhinosinusitis is a more correct word because sinusitis typically accompanies inflammation of the neighboring nasal mucosa. Rhinosinusitis is frequently categorized depending on the length of sinusitis symptoms and inflammation. Acute rhinosinusitis (ARS) is described as sinusitis symptoms lasting over 12 weeks. Chronic rhinosinusitis (CRS) is sinusitis symptoms lasting over 12 weeks. The majority of acute rhinosinusitis is viral in nature and improves on its own.  It is critical to differentiate between viral and bacterial rhinosinusitis to avoid providing ineffective antibiotics against viral infections.

Sinusitis Epidemiology Segmentation

The sinusitis epidemiology section provides insights into the historical and current sinusitis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The sinusitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Sinusitis Prevalent Cases
  • Sinusitis Gender-specific Prevalent Cases
  • Sinusitis Type-specific Cases

Download the report to understand which factors are driving sinusitis epidemiology trends @ Sinusitis Epidemiological Insights

Sinusitis Treatment Market 

Antibiotics, such as amoxicillin, have been suggested as first-line treatment for uncomplicated acute sinusitis for two weeks. The chosen antibiotic must be effective against S. pneumoniae, H. influenza, and M. catarrhalis. Because S. pneumoniae causes rare intracranial and ocular complications of acute bacterial sinusitis, comprehensive coverage for this pathogen is essential. Amoxicillin-clavulanate (Augmentin) is also an effective first-line treatment for acute sinusitis. The inclusion of clavulanate, a beta-lactamase inhibitor, improves H. influenzae and M. catarrhalis coverage. Because of S. pneumoniae resistance, greater amoxicillin dosages (90 mg/kg/day up to 2 g/day) should be investigated.

Cephalosporins such as cefpodoxime proxetil (Vantin) and cefuroxime (Ceftin) are further alternatives for sinusitis treatment. Trimethoprim-sulfamethoxazole (Bactrim), clarithromycin (Biaxin), and azithromycin (Zithromax) may be recommended in individuals allergic to beta-lactams, although they may not provide appropriate coverage for H. influenzae or resistant S. pneumoniae. Penicillin, erythromycin (Suprax), and first-generation cephalosporins such as cephalexin (Keflex, Keftab) are not advised for treating acute sinusitis due to poor antibiotic coverage of the main pathogens.

Mucolytic drugs (guaifenesin) can assist in reducing mucus viscosity for easier clearance and are frequently used in conjunction with decongestants. Some mucolytics are now available over the counter. Saline spray or irrigation can aid in the removal of secretions. Topical corticosteroids are not recommended for acute sinusitis but may benefit chronic sinusitis, nasal polyps, and allergic and nonallergic rhinitis. Antihistamines are not recommended for sinusitis but may be beneficial for underlying allergic rhinitis.

To know more about sinusitis treatment, visit @ Sinusitis Treatment Drugs 

Key Sinusitis Therapies and Companies

  • OPN-375: Optinose US Inc
  • Quinine topical nasal spray: GeneOne Life Science
  • Mometasone eluting resorbable scaffold: Lyra Therapeutics
  • Dupilumab: Sanofi/Regeneron Pharmaceuticals
  • Omalizumab: Genentech
  • Benralizumab: AstraZeneca
  • Telithromycin: Sanofi
  • Moxifloxacin: Bayer
  • PF-06817024: Pfizer

Learn more about the FDA-approved drugs for sinusitis @ Drugs for Sinusitis Treatment 

Sinusitis Market Dynamics

The sinusitis market is expected to change in the coming years. Sinusitis is a common cancer treatment modality. As a result, a large population suffers from sinusitis, creating a massive sinusitis market for any new entrant. Moreover, advancements in radiation delivery technology, such as intensity-modulated radiation treatment, can assist in reducing radiation-induced skin toxicity in specific tumour types, such as breast cancer, will also propel the sinusitis market growth. For those at increased risk of sinusitis, prophylactic administration of a topical steroid is preferred, and topical steroids are often used to treat acute instances. Furthermore, there is some interest in using topical antioxidants or oral enzymes to prevent sinusitis, but no apparent effect has been demonstrated yet.

Furthermore, there is a significant deal of interest in better understanding the processes of dermal injury to mitigate the dermatologic consequences of radiation therapy, but prospective data to guide management are currently scarce. Additionally, the sinusitis pipeline is highly robust; many possible therapies are being studied for sinusitis treatment, and it is safe to assume that the therapeutic space will substantially impact the sinusitis market throughout the forecast period.

However, certain factors may affect the growth of the sinusitis market. Despite developments in radiation delivery technology and rising attention to minimising skin responses, sinusitis management has no gold standard. There are few prospective randomised studies on the use of pharmacologic or supportive care treatments, both topical and non-topical, to prevent and cure sinusitis. Several off-label therapy options are now available on the sinusitis market, each with a sizable sinusitis market share and posing a significant challenge to any new entry in the sinusitis market.

Moreover, the sinusitis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the sinusitis market growth. Furthermore, sinusitis treatment options in cancer have been steadily increasing. This increase in alternative medicines can potentially reduce sinusitis prevalence and hence cause a dip in the growth of the sinusitis market.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
Key Sinusitis Companies Optinose US Inc, GeneOne Life Science, Lyra Therapeutics, Sanofi, Regeneron Pharmaceuticals, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer, TRELLIS BIOSCIENCE, Sanotize Research and Development, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., BEAM Alliance, Insmed Incorporated, Lanier Biotherapeutics, GlycoMira, IVIEW Therapeutics Inc., Nota Laboratories LLC, Quorum Innovations, and others
Key Sinusitis Therapies OPN-375, Quinine topical nasal spray, Mometasone eluting resorbable scaffold, Dupilumab, Omalizumab, Benralizumab, Telithromycin, Moxifloxacin, PF-06817024, and others

Scope of the Sinusitis Market Report

  • Therapeutic Assessment: Sinusitis current marketed and emerging therapies
  • Sinusitis Market Dynamics: Attribute Analysis of Emerging Sinusitis Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Sinusitis Market Access and Reimbursement

Discover more about sinusitis drugs in development @ Sinusitis Clinical Trials

Table of Contents

1. Sinusitis Market Key Insights
2. Sinusitis Market Report Introduction
3. Sinusitis Market Overview at a Glance
4. Sinusitis Market Executive Summary
5. Disease Background and Overview
6. Sinusitis Treatment and Management
7. Sinusitis Epidemiology and Patient Population
8. Patient Journey
9. Sinusitis Marketed Drugs
10. Sinusitis Emerging Drugs
11. Seven Major Sinusitis Market Analysis
12. Sinusitis Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Sinusitis Pipeline

Sinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sinusitis companies, including GeneOne Life Science, Lyra Therapeutics, TRELLIS BIOSCIENCE, Sanotize Research and Development, Sanofi, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., Genentech, Inc., Pfizer, among others.

Sinusitis Epidemiology Forecast

Sinusitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted sinusitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Rhinosinusitis Market

Rhinosinusitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key rhinosinusitis companies, including Kyowa Kirin Co., Ltd., Keymed Biosciences Co.Ltd, Pfizer, GlycoMira Therapeutics, among others.

Rhinosinusitis Pipeline

Rhinosinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rhinosinusitis companies, including Kyowa Kirin Co., Ltd., Keymed Biosciences Co.Ltd, Pfizer, GlycoMira Therapeutics, among others.

Chronic Rhinosinusitis Market

Chronic Rhinosinusitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key chronic rhinosinusitis companies, including Connect Biopharma, Lyra Therapeutics, Sanotize Research and Development corp., Regeneron Pharmaceuticals, AstraZeneca, among others.

Chronic Rhinosinusitis Pipeline

Chronic Rhinosinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic rhinosinusitis companies, including Connect Biopharma, Lyra Therapeutics, Sanotize Research and Development corp., Regeneron Pharmaceuticals, AstraZeneca, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Sinusitis Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation

Published

on

automation-anywhere-appoints-tim-mcdonough-as-chief-marketing-officer-to-drive-global-awareness-and-growth-for-the-leader-in-ai-powered-automation

SAN JOSE, Calif., April 23, 2024 /PRNewswire/ — Automation Anywhere, a leader in AI-powered automation solutions, announced that AI marketing leader ﷟Tim McDonough joined the company as chief marketing officer (CMO). McDonough, who brings more than two decades of experience in driving growth across startups and Fortune 100 companies, will shape and lead Automation Anywhere’s global brand and growth strategies and go-to-market functions.

 
McDonough joins Automation Anywhere from Intel, where he recently served as vice president and CMO of AI and data centers. McDonough oversaw the transformation of the $14 billion-plus business unit, while guiding the company’s strategy and positioning in the AI market.
“Tim joins us at an incredible time in our journey as we experience a new phase of growth ignited by the transformative benefits of our generative AI process automation models that are transforming our customers’ businesses,” said Mihir Shukla, CEO, Automation Anywhere. “Tim’s impressive experience will be instrumental in our efforts to empower organizations to achieve amazing results by automating more than forty percent of workflows and tasks, and saving millions, even billions, of dollars.”
Prior to Intel, McDonough held executive roles at leading technology companies, including Unity Technologies, Qualcomm, and Microsoft. McDonough’s track record of enterprise and C-suite marketing spans developed and emerging technologies, including AI tools, applications, software-as-a-service (SaaS) solutions, and developer ecosystems.
“I’m looking forward to helping lead Automation Anywhere through its next phase growth as it helps companies transform their business,” said McDonough. “Seeing how customers are innovating with Automation Anywhere’s platform demonstrated to me the incredible market opportunity we have. When you combine automation with generative AI, customers can now go beyond task or departmental impact and automate at an enterprise level, empowering companies and employees to do their very best work.”
McDonough’s appointment comes at a time of remarkable opportunity for the company, marked by Automation Anywhere’s recent record-breaking fourth-quarter performance, continued profitability, and strong outlook in its current fiscal year. Last quarter, Automation Anywhere reported 50 percent growth in large enterprise deals from the previous quarter, highlighting the company’s momentum and strong market position.  
About Automation Anywhere  
Automation Anywhere is the leader in AI-powered process automation that puts AI to work across organizations. The company’s Automation Success Platform is powered with generative AI and offers process discovery, RPA, end-to-end process orchestration, document processing, and analytics, with a security and governance-first approach. Automation Anywhere empowers organizations worldwide to unleash productivity gains, drive innovation, improve customer service, and accelerate business growth. The company is guided by its vision to fuel the future of work by unleashing human potential through AI automation. Learn more at http://www.automationanywhere.com/.  
Engage with Automation Anywhere  
WebinarsLinkedInThreadsFacebookInstagramPhoto – https://mma.prnewswire.com/media/2395055/Tim_Headshot.jpgLogo – https://mma.prnewswire.com/media/2383572/4665982/Automation_Anywhere_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/automation-anywhere-appoints-tim-mcdonough-as-chief-marketing-officer-to-drive-global-awareness-and-growth-for-the-leader-in-ai-powered-automation-302125158.html

Continue Reading

Artificial Intelligence

AI Supercomputing Market Growing at +21% CAGR as Industries Evolve Data Analysis

Published

on

ai-supercomputing-market-growing-at-+21%-cagr-as-industries-evolve-data-analysis

USA News Group News Commentary
VANCOUVER, BC, April 23, 2024 /PRNewswire/ — USA News Group News Commentary – Numerous industries are making the shift towards using Artificial Intelligence (AI) supercomputers in leveraging powerful computing systems to address complex challenges, and analyze massive datasets. According to analysts at Markets and Markets the AI supercomputer market is projected to grow at a CAGR of 22% through 2028 to a value of US$3.3 billion. This high level of growth is echoed by analysts at Technavio, who are projecting nearly 21% growth through 2027, however, they are seeing the overall supercomputer market much higher, growing by US$17.6 billion along the way. Several international groups are with massive investments in the billions to evolve their operations to include AI supercomputing, including in Denmark, the UK, Japan, the UAE and the USA. Powering this shift behind the scenes are several tech developers, who this week have been updating the market with their current developments, including: Avant Technologies Inc. (OTC: AVAI), NVIDIA Corporation (NASDAQ: NVDA) (NEO: NVDA), Microsoft Corporation (NASDAQ: MSFT) (NEO: MSFT), D-Wave Quantum Inc. (NYSE: QBTS), and Rigetti Computing, Inc. (NASDAQ: RGTI, RGITW).

The article continued: Moving forward, new regulations and safeguards are being put into place, as seen in the USA when the Biden Administration enacted an AI Executive Order to create new standards for AI safety and security. As well, the Council of the European Union filed a proposal for the regulation of harmonized rules on AI in the EU.
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions
Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an artificial intelligence technology (AI) company specializing in the development of advanced AI and data center infrastructure solutions, announced today that it’s introducing a state-of-the-art supercomputing network and comprehensive licensable dataset. Avant will be collaborating with its technology partner, Wired4Tech, to launch these pivotal developments, which are engineered to accelerate AI adoption and innovation across a broad spectrum of industries.
“Avant’s supercomputing network and our expansive licensable dataset will facilitate significant advancements in AI- driven solutions,” said Danny Rittman, Chief Information Officer of Avant of the launch. “By providing robust computational resources and a rich dataset, Avant is set to eliminate many of the technical and financial barriers that have traditionally hampered AI development. This initiative aims to empower developers with the tools necessary to create more sophisticated and efficient AI models, driving progress and innovation in innumerable fields.”
Highlights of Avant’s Offerings:
Versatile AI Dataset: Available from Q3, this dataset will be regularly updated to support a wide array of AI projects, providing a solid foundation for development, and reducing the time to market for AI solutions.Dynamic Resource Scaling: The network dynamically adjusts computing resources to meet real-time demands, maximizing efficiency and minimizing costs.Accelerated AI Processing: Utilizes cutting-edge distributed computing to dramatically reduce data processing times, enabling rapid iteration and deployment of AI models.Robust Security Measures: Top-tier security protocols are in place to ensure data integrity and compliance with stringent regulatory standards.Seamless Integration: Designed to integrate smoothly with existing AI development environments, minimizing disruptions and simplifying technology adoption.Avant is committed to advancing the AI landscape by providing scalable solutions that will benefit diverse sectors looking to harness the power of artificial intelligence.
CONTINUED… Read this and more news for Avant Technologies at: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
In other industry developments and happenings in the market this week include:
NVIDIA Corporation (NASDAQ: NVDA) (NEO: NVDA), a global leader in providing graphics and compute and networking solutions, recently received an investment of ~US$960 million from Japanese telecommunications company Softbank to enhance its supercomputing power and to support an ambitious generative AI (GenAI) strategy.
Generative AI is increasingly being incorporated into products and services across multiple sectors. A recent projection by Statista, a research firm based in Germany, predicts that the market for generative AI in Japan will expand to approximately $13 billion by 2030, representing a 17x increase from its size in 2023.
Microsoft Corporation (NASDAQ: MSFT) (NEO: MSFT), a global leader in developing and supporting software, services, devises and solutions recently announced it would be investing $1.5 billion into Abu Dhabi’s G42, the leading UAE-based AI tech holding company, to accelerate AI development and global expansion.
“Microsoft’s investment in G42 marks a pivotal moment in our company’s journey of growth and innovation, signifying a strategic alignment of vision and execution between the two organizations,” said H.H. Sheikh Tahnoon bin Zayed Al Nahyan, Chairman of G42. “This partnership is a testament to the shared values and aspirations for progress, fostering greater cooperation and synergy globally.”
G42 will operate its AI applications and services on Microsoft Azure, collaborating to offer advanced AI solutions to global public sector clients and large enterprises. Together, G42 and Microsoft aim to enhance AI and digital infrastructure across the Middle East, Central Asia, and Africa. This collaboration will help these regions gain fair access to services that address key government and business issues, while upholding the highest standards of security and privacy.
D-Wave Quantum Inc. (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers recently announced the launch the first fast-anneal feature, available now on all of D-Wave’s quantum processing units (QPUs) in the LeapTM real-time quantum cloud service. The fast-anneal feature has been central to D-Wave’s key research achievements, as highlighted in publications in Nature Physics and Nature, showing how annealing quantum computing outperforms traditional algorithms in tackling complex optimization problems.
“Providing direct access to Fast Anneal, which has been at the heart of D-Wave’s recent advancements, represents a significant step forward in our mission to provide customers with the resources they need to drive innovation and achieve extraordinary results,” said Dr. Alan Baratz, CEO of D-Wave. “We believe it will further empower them to build industry-shaping applications with the most powerful quantum computing environment available today.”
With enhanced control allowing for notably quicker annealing times than before, this feature enables customers to replicate and expand upon D-Wave’s significant optimization results. Now widely available, this feature allows users to execute quantum computations at unprecedented speeds, significantly mitigating issues like thermal fluctuations and noise that typically disrupt quantum calculations.
Rigetti Computing, Inc. (NASDAQ: RGTI, RGITW), a pioneer in full-stack quantum-classical computing, recently announced the successful completion of its Innovate UK project with Oxford Instruments to launch one of the first UK-based quantum computers. The consortium also included the Quantum Software Lab at the University of Edinburgh, Phasecraft, and Standard Chartered Bank, with financial backing from the UK government’s Quantum Technologies Challenge, led by UK Research & Innovation (UKRI).
 “Completing this project, with the end result being a useful 32-qubit quantum computer, is an exceptional achievement for all of the project partners,” said Dr. Subodh Kulkarni, CEO of Rigetti. “It takes a world-class team to build and deploy a quantum computer. The UK has become a world leader in quantum computing technologies, and we are excited to continue to contribute to its quantum computing capabilities. Additionally, Rigetti plans to leverage this experience to continue to develop our UK quantum computing leadership as we embark on deploying a 24-qubit Ankaa-class quantum computer at the NQCC’s Harwell campus.”
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 
CONTACT:USA NEWS [email protected] (604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/ai-supercomputing-market-growing-at-21-cagr-as-industries-evolve-data-analysis-302124990.html

Continue Reading

Artificial Intelligence

Artificial Intelligence Investment Soars to Trillions, Sparking Regulatory Interest

Published

on

artificial-intelligence-investment-soars-to-trillions,-sparking-regulatory-interest

USA News Group Commentary
VANCOUVER, BC, April 23, 2024 /PRNewswire/ — USA News Group – In just a few years, the potential generated by the rise of Artificial Intelligence (AI) continues to entice investment to the tune of many trillions, with McKinsey & Company projecting generative AI to generate up to $7.9 trillion alone annually. It’s a sector that’s still in its early stages, and with that comes plenty of scrutiny, including the recent actions by US regulators regarding whether or not investors of OpenAI were misled, through an SEC inquiry launched in February. All the while, corporate AI investment is surging, with several companies benefitting including NVIDIA Corporation (NASDAQ:NVDA) (NEO:NVDA), Meta Platforms Inc. (NASDAQ:META) (NEO:META), Apple Inc. (NASDAQ:AAPL) (NEO:AAPL), C3.ai, Inc. (NYSE:AI), and Avant Technologies Inc. (OTC:AVAI).

Looking to help unlock the full potential of AI, Avant Technologies Inc. (OTC:AVAI) is pursuing its stated mission to build the nation’s first supercomputing network to provide big data and AI software companies with a faster, more powerful, and more cost-effective compute infrastructure. Recently Avant signed a co-development agreement with Wired4Tech, Inc. to create high-density compute infrastructure and supercomputer network software to move the company closer to achieving this mission.
“The technological innovations that we expect this collaboration to yield will help to usher in a new era of performance, cost efficiency and environmental sustainability for AI and Big Data,” said Timothy Lantz, CEO of Avant. “We have made exciting progress in the past several months, and we believe this partnership will further help to accelerate speed-to-market of our next generation solutions.”
The Wired4Tech collaboration aims to assist in the final stages of development and testing for Avant’s new high-density private cloud infrastructure solution. Additionally, it will start to establish the groundwork for Avant’s proposed AI supercomputing network. Avant expects to launch its next-generation infrastructure solution sometime in the first half of 2024.
“We’re at an inflection point where accelerated computing and generative AI have come together to speed innovation at an unprecedented pace,” said Paul Averill, Founder and CEO of Wired4Tech. “Our partnership with Avant Technologies will help AI companies accelerate their work with infrastructure, software and services that drive efficiency and reduce costs. There is no AI without the right infrastructure and Avant will lead the way with its unique and innovative and cost-effective AI platform.”
The collaboration was a follow-up to Avant’s announcement that the company is set to leverage its proprietary AI to drive proactive, next-generation data center security, through its enhancements to Avant! AI™, that seamlessly integrates with industry-standard data science tools and algorithms, enabling organizations to harness the power of data for deeper insights and informed decision-making.
“The rapid advancements in AI are unlocking tremendous opportunities and potential across almost every facet of our lives, but those same advancements can also pose an increased threat when used by those with an intent to harm,” said Lantz. “In today’s digital world cybersecurity is of paramount importance and Avant is committed to providing our customers with the necessary tools to ensure the safety and security of their information and that of their end-users.”
The planned improvements in Avant’s proprietary gen AI are designed to achieve two main goals: to provide early detection of potential security vulnerabilities and to offer recommendations for proactive measures to strengthen cybersecurity baselines, reduce risks, and ensure compliance in the ever-changing digital environment.
Under the hood of many of the biggest AI setups today are products from NVIDIA Corporation (NASDAQ:NVDA) (NEO:NVDA), which has seen its market cap surge to more than $2 trillion based upon an insatiable AI chip demand. This includes mega investments from some of the largest tech companies on the planet, including Meta Platforms Inc. (NASDAQ:META) (NEO:META) which is spending billions of dollars on Nvidia’s AI chips.
Shared through an Instagram Reels post by CEO Mark Zuckerberg, Meta’s “future roadmap” for AI requires the construction of “an absolutely massive amount of infrastructure.” By the end of 2024, Zuckerberg mentioned that this infrastructure will comprise 350,000 H100 graphics cards from Nvidia—which were being sold for more than $40,000 on eBay as recently as last April.
The ramp up of GPUs for Meta is projected to cost as much as $18 billion by the end of 2024. The ambitious loading up of infrastructure is similar to Meta’s $13 billion spent on Reality Labs, its metaverse division in 2022.
Competition for computing power will be ramping up, as Apple Inc. (NASDAQ:AAPL) (NEO:AAPL) has signalled the company will be investing significantly in generative AI, as it moves away from its self-driving electric car project. So far, Apple CEO Tim Cook hasn’t launched any competing products to models like OpenAI’s GPT or Google’s Gemini, but he has already teased a major announcement that the company will “break new ground” in GenAI coming later this year.
“AI is woven into our users’ lives for all sorts of tasks, from the everyday to the essential,” said Tim Cook. “AI allows Apple Watch to help you track your workouts, automatically detecting whether you’re taking a walk or going for a swim. It enables your iPhone to call for help if you’re in a car accident.”
While Cook’s sentiments hint towards Apple moving more towards AI investment, the company’s investors have grown impatient with the tech giant after lagging behind its mega-tech peers who have shared much clearer AI strategies.
Enterprise AI application software company C3.ai, Inc. (NYSE:AI) is coming off of a healthy Q3 2024 financial results announcement, where they saw total revenue grow 18% year-over-year to $78.4 million, exceeding their guidance range. Perhaps more importantly, C3 AI saw its customer engagement grow 80% year-over-year, and a 23% increase in subscription revenue.
“Generative AI use cases continue to influence customer engagement, with 17 of 29 total pilots signed in the quarter driven by generative AI,” said Kingsley Crane, analyst at Canaccord Genuity, about C3 AI in a report. “So far, the company has been converting pilots into full-time customers roughly near the assumed spend levels of $210,000 per quarter, even if some pilots have pushed a bit beyond the initially planned six months and started a bit lower than $500,000 contribution over two quarters. If C3 can continue the sequential growth in product revenue we’ve seen over the past three quarters, the firm is on track to grow over 30%.”
Among the customer base that C3 AI has been working with is biotech giant Genentech, to improve the complex biologics manufacturing process with AI. Genentech began using the AI application in 2021 to ensure centrifuges in their facility remained operational, with patients benefitting by receiving their medicines on time. In 2022, the biotech developer would go on to expand its use of C3’s assets beyond centrifuges, to around 200 pieces of equipment in total. Now Genentech has nearly 200 users including data scientists and facility managers who are trained to use the C3 AI platform, and regularly use the AI application to evaluate equipment health and maintain manufacturing operations.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA News Group
[email protected]
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/artificial-intelligence-investment-soars-to-trillions-sparking-regulatory-interest-302124950.html

Continue Reading

Trending